<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The Challenge-<z:hpo ids='HP_0001297'>Stroke</z:hpo> study was conducted in Japanese patients initiated on <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil therapy within 3 months of suffering a <z:hpo ids='HP_0001297'>stroke</z:hpo> to investigate the clinical use of <z:chebi fb="0" ids="3347">candesartan</z:chebi> and its efficacy/safety in this therapeutic setting </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 869 patients formed the safety analysis set </plain></SENT>
<SENT sid="2" pm="."><plain>In total, 79.6% of patients with brain <z:mp ids='MP_0001914'>hemorrhage</z:mp> (BH) and 60.2% with <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (BI) began <z:chebi fb="0" ids="3347">candesartan</z:chebi> before post-<z:hpo ids='HP_0001297'>stroke</z:hpo> day 3 and 7, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Baseline average blood pressure (BP) was 152.0/83.2 mmHg in the BH group and 165.2/89.8 mmHg in the BI group; this was reduced to 125.8/75.4 mmHg and 136.3/78.1 mmHg, respectively, at 1 year </plain></SENT>
<SENT sid="4" pm="."><plain>The incidence of adverse drug reactions was 6.7 and 8.0%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>There were 12 recurrent <z:hpo ids='HP_0001297'>strokes</z:hpo> in the BH group and 11 in the BI group after 1 year </plain></SENT>
<SENT sid="6" pm="."><plain>The risk of recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo> was significantly higher for BH patients with a final systolic BP â‰¥150 mmHg than for those with a final systolic BP &lt;130 mmHg (hazard ratio: 6.807; p = 0.004) </plain></SENT>
<SENT sid="7" pm="."><plain>Aggressive <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> therapy is currently employed in Japanese patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> was safe and effective for BP control in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>Strict BP management may be useful for secondary prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> after BH </plain></SENT>
</text></document>